The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas

Cancer Letters

Volumn 178, Issue 2, 2002, Pages 209-217

  Eikesdal, Hans Petter ^a   Landuyt, Willy ^b   Dahl, Olav ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Anti vascular therapy; Combretastatin A 4 disodium phosphate; Drug distribution; Interstitial fluid pressure; Tumor volume; Vinblastine

Indexed keywords

COMBRETASTATIN A4; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG TRANSPORT; FEMALE; FLUORESCENCE; GLIOMA; MALE; NECK TUMOR; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID TUMOR; TISSUE PRESSURE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG DELIVERY SYSTEMS; EXTRACELLULAR SPACE; FEMALE; GLIOMA; MALE; NEOPLASM TRANSPLANTATION; PRESSURE; RATS; STILBENES; VINBLASTINE;

EID: 0037171583     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(01)00835-7     Document Type: Article

References (48)

1. Antiangiogenesis is produced by nontoxic doses of vinblastine
2. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
3. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
4. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism
5. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
6. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
7. Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors
8. Effects of novel and conventional anti-cancer agents on human endothelial permeability: Influence of tumour secreted factors
9. Targeting tumour vasculature: The development of combretastatin A4
10. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma
11. Vinblastine and hyperthermia targets the tumor vasculature in BT4An rat gliomas: Therapeutic implications of the vascular phenotype
12. Barriers to drug delivery in solid tumors
13. Vascular targeting of solid tumours, a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas
14. Combretastatin a4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model
15. A cerebral glioma model for experimental therapy and in vivo invasion studies in syngenic BD IX rats
16. The pharmacology of dimethyl sulfoxide
17. Midazolam and fentanyl-fluanisone: Assessment of anesthetic effect in laboratory rodents and rabbits
18. Interstitial fluid pressure in rats measured with a modified wick technique
19. Laminin expression by glial fibrillary acidic protein positive cells in human gliomas
20. Vascular and interstitial transport in tumors
21. Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules
22. Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralleled by an increased uptake of (51)Cr-EDTA
23. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: Clinical implications
24. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability
25. Integrins and control of interstitial fluid pressure
26. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: Implications for vascular collapse
27. The susceptibility of tumors to the antivascular drug combretastatin a4 phosphate correlates with vascular permeability
28. Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide
29. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
30. Relationship between heat-induced vascular damage and thermosensitivity in four mouse tumors
31. Tumor angiogenesis: Past, present and the near future
32. Vascular attack as a therapeutic strategy for cancer
33. The cell proliferation kinetics of the EMT6/M/AC mouse tumour at four volumes during unperturbed growth in vivo
34. Cell kinetics and chemotherapy: A critical review
35. Tumor size dependent changes in a murine fibrosarcoma: Use of in vivo 31P NMR for non-invasive evaluation of tumor metabolic status
36. Disparate responses of tumour vessels to angiotensin II: Tumour volume-dependent effects on perfusion and oxygenation
37. Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interaction of the drugs with radiation
38. 3H]vinblastine in tumor and host tissues of Nb rats bearing a transplantable lymphoma which is sensitive to the alkaloid
39. Reduced tumor oxygenation by treatment with vinblastine
40. Effects of noradrenaline on interstitial fluid pressure in induced rat mammary tumours
41. Interstitial fluid pressure in DMBA-induced rat mammary tumours
42. Measurement of interstitial fluid pressure in dogs: Evaluation of methods
43. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: Changes during treatment
44. Characterization of neuroblastoma xenograft in rat flank. I. Growth, interstitial fluid pressure, and interstitial fluid velocity distribution profiles
45. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy
46. Changes in vessel pressure and interstitial fluid pressure of normal subcutis and subcutaneous tumor in rats due to angiotensin II
47. Interstitial fluid pressure in intracranial tumours in patients and in rodents
48. Interstitial hypertension in head and neck tumors in patients: Correlation with tumor size